Literature DB >> 33933582

Dual specific phosphatases (DUSPs) in cardiac hypertrophy and failure.

Michael Mutlak1, Izhak Kehat2.   

Abstract

Pressure overload and other stress stimuli elicit a host of adaptive and maladaptive signaling cascades that eventually lead to cardiac hypertrophy and heart failure. Among those, the mitogen-activated protein kinase (MAPK) signaling pathway has been shown to play a prominent role. The dual specificity phosphatases (DUSPs), also known as MAPK specific phosphatases (MKPs), that can dephosphorylate the MAPKs and inactivate them are gaining increasing attention as potential drug targets. Here we try to review recent advancements in understanding the roles of the different DUSPs, and the pathways that they regulate in cardiac remodeling. We focus on the regulation of three main MAPK branches - the p38 kinases, the c-Jun-N-terminal kinases (JNKs) and the extracellular signal-regulated kinases (ERK) by various DUSPs and try to examine their roles.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac hypertrophy; Dual specificity phosphatases; Mitogen activated protein kinases

Mesh:

Substances:

Year:  2021        PMID: 33933582     DOI: 10.1016/j.cellsig.2021.110033

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  3 in total

Review 1.  Dual-Specificity Phosphatases and Kidney Diseases.

Authors:  Haiyang Li; Jiachuan Xiong; Yu Du; Yinghui Huang; Jinghong Zhao
Journal:  Kidney Dis (Basel)       Date:  2021-12-01

Review 2.  Friend or foe? Unraveling the complex roles of protein tyrosine phosphatases in cardiac disease and development.

Authors:  Maike Krenz
Journal:  Cell Signal       Date:  2022-03-05       Impact factor: 4.850

3.  The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2-GATA4 Signaling Pathway.

Authors:  Kana Shimizu; Yoichi Sunagawa; Masafumi Funamoto; Hiroki Honda; Yasufumi Katanasaka; Noriyuki Murai; Yuto Kawase; Yuta Hirako; Takahiro Katagiri; Harumi Yabe; Satoshi Shimizu; Nurmila Sari; Hiromichi Wada; Koji Hasegawa; Tatsuya Morimoto
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.